Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG

Affiliations

• ¹ Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
• ² Centre of Trials Research, Cardiff University, Cardiff, UK.
• ³ Department of Biostatistics, University of Washington, Seattle, WA, USA.
• ⁴ Department of Haematology, The University of Bristol, Bristol, UK.
• ⁵ Nuffield Department of Population Health, University of Oxford, Oxford, UK.
• ⁶ Paul O'Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, UK.
• ⁷ Loyola University Medical Center, Maywood, IL, USA.
• ⁸ Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal, Canada.
• ⁹ Department of Medicine, Division of Hematology/Oncology, The Medical College of Wisconsin, Milwaukee, WI, USA.
• ¹⁰ Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA.
• ¹¹ School of Medicine, Nottingham University, Nottingham, UK.
• ¹² Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
• ¹³ Division of Hematology/Department of Medicine, University of Washington, Seattle, WA, USA.
• ¹⁴ Department of Epidemiology, University of Washington, Seattle, WA, USA.
• ¹⁵ Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA, USA.
• ¹⁶ Christie Hospital, Manchester, UK.